Search

Displaying results 6601 - 6610 of 10000 in total
  1. Drug

    DLO6002

    go.drugbank.com/drugs/DB05179
    Experimental

    DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.

  2. Drug

    HCV-086

    go.drugbank.com/drugs/DB05884
    Experimental

    HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.

  3. Drug

    Methadyl acetate

    go.drugbank.com/drugs/DB01433
    ExperimentalIllicit

    It is used mainly in the treatment of narcotic dependence.

  4. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  5. Drug

    Aluminum zirconium trichlorohydrex gly

    go.drugbank.com/drugs/DB11116
    ApprovedWithdrawn

    The compound forms a colloidal plug in sweat pores, preventing sweat from leaving the body. … Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.

  6. Drug

    NCX 950

    go.drugbank.com/drugs/DB05849
    Experimental

    NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.

  7. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  8. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  9. Drug

    CD68-ET3-LV

    go.drugbank.com/drugs/DB32864
    Investigational

    CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

  10. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    It is an inhibitor of the A subunit of bacterial DNA gyrase.

    Synonyms: 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure